A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.

Hum Vaccin Immunother · 2021 · PMC8475590 · PMID 33661716

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The IgG responses to the seven vaccine serotypes showed a trend consistent with the OPA responses (Supplementary Figure 2).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.